In other words, subjects with both atherogenic dyslipidemia marked by high Apo CIII concentrations and a clinical history coherent with an elevated risk marked by high CHA2DS2-VASc score resulted at the highest risk of ischemic stroke/TIA in spite of anticoagulant treatment, thus being potentially the “best target” for more aggressive therapeutic approaches aiming at the reduction of cerebral ischemic events. Here, APOC3 is linked to transient ischemic attack.